Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Piperacillin-Tazobactam vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Community-acquired pneumonia,Nosocomial pneumonia,Septicemia,Febrile neutropenia (off-label),Bone and joint infections (off-label)
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Piperacillin: ~0.7-1.2 hours (normal renal function); Tazobactam: ~0.9-1.3 hours. Prolonged in renal impairment (e.g., piperacillin half-life up to 3-6 hours in ESRD).
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Piperacillin undergoes minor hepatic metabolism; tazobactam is metabolized to a minor inactive metabolite. Both are primarily excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Piperacillin: ~68% renal excretion as unchanged drug, ~20% biliary/fecal. Tazobactam: ~80% renal excretion as unchanged drug, remainder as inactive metabolite.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Piperacillin: ~30% bound to albumin; Tazobactam: ~30% bound to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Piperacillin: ~0.18-0.3 L/kg; Tazobactam: ~0.2-0.3 L/kg. Distributes widely into tissues, including lung, kidney, bile, peritoneal fluid, and inflamed tissues.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
IV only; oral bioavailability negligible (not orally administered).
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Cr Cl 20-40 m L/min: 2.25 g IV every 6 hours; Cr Cl <20 m L/min: 2.25 g IV every 8 hours; hemodialysis: 2.25 g IV every 12 hours, plus 0.75 g after dialysis.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No dosage adjustment required for hepatic impairment. Use caution in patients with hepatic encephalopathy or severe hepatic dysfunction.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Infants and children: 100 mg piperacillin/kg/dose IV every 6-8 hours (max 4 g piperacillin per dose); for pseudomonal infections, up to 200 mg/kg/dose IV every 6 hours.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Start at the lower end of dosing; adjust primarily based on renal function. Monitor renal function closely and modify dose according to creatinine clearance.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
No FDA black box warnings.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Hypersensitivity reactions including anaphylaxis,Clostridioides difficile-associated diarrhea,Hematologic toxicity (neutropenia, thrombocytopenia) with prolonged therapy,Renal impairment requiring dose adjustment,Electrolyte disturbances (hypokalemia),Neuromuscular irritability or seizures with high doses or renal failure
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to piperacillin, tazobactam, or any beta-lactam antibiotic,History of anaphylactic reaction to penicillins, cephalosporins, or carbapenems
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No significant food interactions; take with or without food. Avoid alcohol during therapy.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is generally acceptable for serious infections.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Piperacillin and tazobactam are excreted into human milk in low concentrations. M/P ratio for piperacillin is approximately 0.11. No adverse effects on nursing infants are anticipated. Use with caution, especially if breastfeeding a premature infant or one with renal impairment.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No dose adjustment is routinely required for pregnancy alone. However, pregnancy-related increases in renal clearance may necessitate higher doses or more frequent administration for severe infections. Monitor clinical response and consider therapeutic drug monitoring.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Piperacillin-tazobactam (Zosyn) exhibits time-dependent killing; optimal efficacy requires frequent dosing (every 6 hours) with extended infusion (4 hours) for critically ill patients. Adjust dose for renal impairment; Cr Cl <20 m L/min: max 2.25 g every 8 hours. Monitor for bleeding risk due to platelet dysfunction at high doses. Contains sodium (2.79 m Eq per gram of piperacillin); caution in heart failure. Do not co-administer with aminoglycosides in same IV line; use separate sites.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Take this medication exactly as prescribed; do not skip doses even if feeling better.,Report any signs of allergic reaction (rash, hives, difficulty breathing) immediately.,This drug may cause diarrhea, nausea, or headache; contact your doctor if severe or persistent.,Inform your doctor if you have kidney disease, heart failure, or bleeding disorders.,Avoid alcohol while taking this medication to reduce risk of adverse effects.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
"Tazobactam, a beta-lactamase inhibitor, may reduce the therapeutic efficacy of picosulfuric acid, a stimulant laxative, by altering gut microbiota composition and reducing bacterial enzymatic conversion of the prodrug to its active metabolite. This can lead to diminished laxative effect and inadequate bowel preparation for colonoscopy. Patients may experience suboptimal colonic cleansing, potentially compromising diagnostic accuracy."
"Tazobactam, a beta-lactamase inhibitor, may reduce the serum concentration of doxorubicin, an anthracycline antineoplastic agent, potentially decreasing its cytotoxic efficacy. This interaction is hypothesized to occur through tazobactam's induction of drug transporters such as P-glycoprotein, enhancing doxorubicin efflux and lowering intracellular accumulation. Reduced doxorubicin exposure could compromise therapeutic outcomes in cancer patients, increasing the risk of treatment failure."
"Tazobactam, a beta-lactamase inhibitor, can reduce the serum concentration of Netilmicin, an aminoglycoside antibiotic, potentially diminishing its bactericidal efficacy. This interaction likely occurs through physicochemical inactivation in vivo, where beta-lactam compounds form a covalent bond with the aminoglycoside's amino groups, reducing its antimicrobial activity. Clinically, this may lead to subtherapeutic aminoglycoside levels, treatment failure, or increased risk of infection progression, particularly in immunocompromised patients."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Piperacillin-Tazobactam vs ACTIQ, answered by our medical review team.
Piperacillin-Tazobactam is a Penicillin Antibiotic + Beta-Lactamase Inhibitor that works by Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Tazobactam is a beta-lactamase inhibitor that irreversibly inhibits beta-lactamases, preventing degradation of piperacillin.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Piperacillin-Tazobactam and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Piperacillin-Tazobactam is: 3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours; for nosocomial pneumonia, 4.5 g IV every 6 hours.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Piperacillin-Tazobactam and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Piperacillin-Tazobactam is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Insufficient human data for first trimester; consider benefit vs risk. Second and third trimester use is . ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.